Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib in Moderate-to-Severe Plaque Psoriasis
NCT01490632Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2011
- Primary completion
- Dec 2012
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Antibody-Based Therapeutics
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial of baricitinib in plaque psoriasis (5 arms), sponsored by Eli Lilly and Company. Primary endpoint: Percentage of Participants Achieving Psoriasis Area and Severity Index Score ≥75% Improvement at 12 weeks. Started Dec 2011; status: completed.
02
Drugs
baricitinib
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT01490632.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01490632.